Skip Navigation

Annals of Oncology 2007 18(7):1129-1131; doi:10.1093/annonc/mdm129
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow E-letters: View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bernardi, A
Right arrow Articles by Bonavina, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bernardi, A
Right arrow Articles by Bonavina, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

editorial

Allocation of public sources in oncology: which role can ethics play?

A Bernardi1,*, A Jirillo2, R Pegoraro3 and MG Bonavina4

1 Ethics Committee, IRCCS—Istituto Oncologico Veneto, Padova
2 Medical Oncology Unit, IRCCS—Istituto Oncologico Veneto, Padova
3 Fondazione Lanza, Padova
4 Healthcare Management Department, IRCCS—Istituto Oncologico Veneto, Padova, Italy

* (E-mail: alessandra.bernardi@istitutoncologicoveneto.it)

The first 150 words of the full text of this article appear below.

By 2008, anticancer drugs will be the leading therapeutic area in term of sales. This appraisal has been done by the Intercontinental Marketing Services (IMS) Health [1], a provider of business intelligence and strategic consulting services for the pharmaceutical and ‘health care’ industries. Oncology, considered a niche sector just a few years ago, will reach a business volume of 41 billion dollars in 2008 compared with 24 billion dollars in 2004. The economic aspects will increasingly restrict access to new and expensive oncological drugs (e.g. Targeted therapy as monoclonal antibodies and angiogenesis inhibitors) in different health care realities.

A report by the Karolinska Institutet [2], in conjunction with the Stockholm School of Economics, exposes current stark inequalities in patient access to cancer treatment across Europe. The report found that patients across Europe do not have equality of access to new cancer drugs and the speed at . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
A. Jirillo, F. Vascon, and M. Giacobbo
Bevacizumab in advanced cancer, too much or too little?
Ann. Onc., October 1, 2008; 19(10): 1817 - 1818.
[Full Text] [PDF]

Home page
 Ann OncolHome page
D. J. Kerr Editor-in-
New wave
Ann. Onc., January 1, 2008; 19(1): 3 - 4.
[Full Text] [PDF]

E-letters:

Read all E-letters

A Reply to Bernardi, et al.
Kenneth Alonso, et al.
Annals of Oncology, 15 Jan 2008 [Full text]